BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38622549)

  • 1. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
    Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
    BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    Kondili LA; Craxì L; Nava F; Babudieri S; D'Ambrosio R; Marcellusi A; Mennini FS; Valle S; Russo P; Olimpieri PP; Andreoni M; Aghemo A
    J Infect Dis; 2023 Sep; 228(Suppl 3):S211-S220. PubMed ID: 37703346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
    Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
    Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.
    Selfridge M; Barnett T; Lundgren K; Guarasci K; Milne R; Drost A; Fraser C
    Public Health Nurs; 2022 Sep; 39(5):1009-1016. PubMed ID: 35537120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
    Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
    Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
    Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
    Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.
    Tien HM; Cheng TC; Lien HC; Yang KF; Shy CG; Chen YL; Hsu NT; Lu SN; Wang JH
    Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
    Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.